Jewish General Hospital/Lady Davis Institute for Medical Research
Co-Applicant: Dr. Nathalie Johnson
Collaborator: Dr. Francois Mercier
Blood cancer type
Uncovering novel chemoresistance driver mutations in Burkitt's lymphoma
Blood cancers disrupt the normal functioning of our blood cells and can be diagnosed during childhood up to late adulthood. Although anti-cancer therapies have dramatically improved over the past decades, patients affected by these diseases are still at high risk of being unresponsive or developing resistance to the current standard treatments. The goal of this research proposal is to use newly developed technologies that allow editing of the genome to identify new diagnostic tools for a specific subtype of blood cancers, named Burkitt's Lymphoma (BL). We aim at functionally characterizing mutations observed in patients that have experienced chemotherapy relapse in a mouse model and determine which mutations provide a selective advantage to the tumour. This work will not only provide help in the diagnosis of BL but will also greatly enhance the development of new therapies for BL patients that fail conventional treatments.